Insights on the Prostate Cancer Chemotherapy Drugs Market Report & Forecast to 2028 – by Players, Types, Applications and Region
QYResearch released a latest market research report on the Global and United States Prostate Cancer Chemotherapy Drugs market, which is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the Global Prostate Cancer Chemotherapy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
Scope of the Prostate Cancer Chemotherapy Drugs Market Report
This report focuses on global and United States Prostate Cancer Chemotherapy Drugs market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Prostate Cancer Chemotherapy Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Abiraterone Acetate accounting for % of the Prostate Cancer Chemotherapy Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Hospital Pharmacy was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
For more information about this report, visit
Key Questions Answered in This Report
How has the Global and United States Prostate Cancer Chemotherapy Drugs performed so far and how will it perform in the coming years?
What are the key regional markets?
What is the breakup of the market based on the Prostate Cancer Chemotherapy Drugs type?
What is the breakup of the market based on the application?
What is the breakup of the market size based on the region?
What is the breakup of the market based on the region Level & country Level?
Who are the key players of the Global and United States Prostate Cancer Chemotherapy Drugs?
Segments Covered in the Report
Segment by Type
Abiraterone Acetate
Apalutamide
Bicalutamide
Cabazitaxel
Others
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Sales
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Johnson & Johnson
Pfizer
Roche
Novartis
AbbVie
Bristol-Myer
Sanofi
AstraZeneca
Merck
Amgen
Bayer AG
Ipsen Group
Endo Pharmaceuticals
Dendreon Corporation
Myovant Biosciences
Effector Therapeutics
Mediolanum
ESSA Pharma
Astellas Pharma
Janssen
Eli Lilly and Company
POINT Biopharma
Hinnova Pharmaceuticals
Sophiris Bio
Ultimovacs
Foresee Pharmaceuticals
Luye Pharma Group
Abbott
Jiangsu HengRui Medicine
Key Topics Covered
1 Study Coverage
2 Prostate Cancer Chemotherapy Drugs by Platform
3 Prostate Cancer Chemotherapy Drugs by Application
4 Global Prostate Cancer Chemotherapy Drugs Competitor Landscape by Company
5 Global Prostate Cancer Chemotherapy Drugs Market Size by Region
5.1 Global Prostate Cancer Chemotherapy Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Prostate Cancer Chemotherapy Drugs Market Size by Region (2017-2028)
5.2.1 Global Prostate Cancer Chemotherapy Drugs Market Size by Region: 2017-2022
5.2.2 Global Prostate Cancer Chemotherapy Drugs Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Prostate Cancer Chemotherapy Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Prostate Cancer Chemotherapy Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 United States
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Prostate Cancer Chemotherapy Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Prostate Cancer Chemotherapy Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe Prostate Cancer Chemotherapy Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Prostate Cancer Chemotherapy Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Prostate Cancer Chemotherapy Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Prostate Cancer Chemotherapy Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Prostate Cancer Chemotherapy Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Prostate Cancer Chemotherapy Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Corporation Information
7.1.2 Johnson & Johnson Description and Business Overview
7.1.3 Johnson & Johnson Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Johnson & Johnson Prostate Cancer Chemotherapy Drugs Products Offered
7.1.5 Johnson & Johnson Recent Development
7.2 Pfizer
7.2.1 Pfizer Corporation Information
7.2.2 Pfizer Description and Business Overview
7.2.3 Pfizer Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Pfizer Prostate Cancer Chemotherapy Drugs Products Offered
7.2.5 Pfizer Recent Development
7.3 Roche
7.3.1 Roche Corporation Information
7.3.2 Roche Description and Business Overview
7.3.3 Roche Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Roche Prostate Cancer Chemotherapy Drugs Products Offered
7.3.5 Roche Recent Development
7.4 Novartis
7.4.1 Novartis Corporation Information
7.4.2 Novartis Description and Business Overview
7.4.3 Novartis Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Novartis Prostate Cancer Chemotherapy Drugs Products Offered
7.4.5 Novartis Recent Development
7.5 AbbVie
7.5.1 AbbVie Corporation Information
7.5.2 AbbVie Description and Business Overview
7.5.3 AbbVie Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 AbbVie Prostate Cancer Chemotherapy Drugs Products Offered
7.5.5 AbbVie Recent Development
7.6 Bristol-Myer
7.6.1 Bristol-Myer Corporation Information
7.6.2 Bristol-Myer Description and Business Overview
7.6.3 Bristol-Myer Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Bristol-Myer Prostate Cancer Chemotherapy Drugs Products Offered
7.6.5 Bristol-Myer Recent Development
7.7 Sanofi
7.7.1 Sanofi Corporation Information
7.7.2 Sanofi Description and Business Overview
7.7.3 Sanofi Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Sanofi Prostate Cancer Chemotherapy Drugs Products Offered
7.7.5 Sanofi Recent Development
7.8 AstraZeneca
7.8.1 AstraZeneca Corporation Information
7.8.2 AstraZeneca Description and Business Overview
7.8.3 AstraZeneca Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 AstraZeneca Prostate Cancer Chemotherapy Drugs Products Offered
7.8.5 AstraZeneca Recent Development
7.9 Merck
7.9.1 Merck Corporation Information
7.9.2 Merck Description and Business Overview
7.9.3 Merck Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Merck Prostate Cancer Chemotherapy Drugs Products Offered
7.9.5 Merck Recent Development
7.10 Amgen
7.10.1 Amgen Corporation Information
7.10.2 Amgen Description and Business Overview
7.10.3 Amgen Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Amgen Prostate Cancer Chemotherapy Drugs Products Offered
7.10.5 Amgen Recent Development
7.11 Bayer AG
7.11.1 Bayer AG Corporation Information
7.11.2 Bayer AG Description and Business Overview
7.11.3 Bayer AG Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Bayer AG Prostate Cancer Chemotherapy Drugs Products Offered
7.11.5 Bayer AG Recent Development
7.12 Ipsen Group
7.12.1 Ipsen Group Corporation Information
7.12.2 Ipsen Group Description and Business Overview
7.12.3 Ipsen Group Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Ipsen Group Products Offered
7.12.5 Ipsen Group Recent Development
7.13 Endo Pharmaceuticals
7.13.1 Endo Pharmaceuticals Corporation Information
7.13.2 Endo Pharmaceuticals Description and Business Overview
7.13.3 Endo Pharmaceuticals Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Endo Pharmaceuticals Products Offered
7.13.5 Endo Pharmaceuticals Recent Development
7.14 Dendreon Corporation
7.14.1 Dendreon Corporation Corporation Information
7.14.2 Dendreon Corporation Description and Business Overview
7.14.3 Dendreon Corporation Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Dendreon Corporation Products Offered
7.14.5 Dendreon Corporation Recent Development
7.15 Myovant Biosciences
7.15.1 Myovant Biosciences Corporation Information
7.15.2 Myovant Biosciences Description and Business Overview
7.15.3 Myovant Biosciences Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Myovant Biosciences Products Offered
7.15.5 Myovant Biosciences Recent Development
7.16 Effector Therapeutics
7.16.1 Effector Therapeutics Corporation Information
7.16.2 Effector Therapeutics Description and Business Overview
7.16.3 Effector Therapeutics Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Effector Therapeutics Products Offered
7.16.5 Effector Therapeutics Recent Development
7.17 Mediolanum
7.17.1 Mediolanum Corporation Information
7.17.2 Mediolanum Description and Business Overview
7.17.3 Mediolanum Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.17.4 Mediolanum Products Offered
7.17.5 Mediolanum Recent Development
7.18 ESSA Pharma
7.18.1 ESSA Pharma Corporation Information
7.18.2 ESSA Pharma Description and Business Overview
7.18.3 ESSA Pharma Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.18.4 ESSA Pharma Products Offered
7.18.5 ESSA Pharma Recent Development
7.19 Astellas Pharma
7.19.1 Astellas Pharma Corporation Information
7.19.2 Astellas Pharma Description and Business Overview
7.19.3 Astellas Pharma Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.19.4 Astellas Pharma Products Offered
7.19.5 Astellas Pharma Recent Development
7.20 Janssen
7.20.1 Janssen Corporation Information
7.20.2 Janssen Description and Business Overview
7.20.3 Janssen Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.20.4 Janssen Products Offered
7.20.5 Janssen Recent Development
7.21 Eli Lilly and Company
7.21.1 Eli Lilly and Company Corporation Information
7.21.2 Eli Lilly and Company Description and Business Overview
7.21.3 Eli Lilly and Company Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.21.4 Eli Lilly and Company Products Offered
7.21.5 Eli Lilly and Company Recent Development
7.22 POINT Biopharma
7.22.1 POINT Biopharma Corporation Information
7.22.2 POINT Biopharma Description and Business Overview
7.22.3 POINT Biopharma Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.22.4 POINT Biopharma Products Offered
7.22.5 POINT Biopharma Recent Development
7.23 Hinnova Pharmaceuticals
7.23.1 Hinnova Pharmaceuticals Corporation Information
7.23.2 Hinnova Pharmaceuticals Description and Business Overview
7.23.3 Hinnova Pharmaceuticals Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.23.4 Hinnova Pharmaceuticals Products Offered
7.23.5 Hinnova Pharmaceuticals Recent Development
7.24 Sophiris Bio
7.24.1 Sophiris Bio Corporation Information
7.24.2 Sophiris Bio Description and Business Overview
7.24.3 Sophiris Bio Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.24.4 Sophiris Bio Products Offered
7.24.5 Sophiris Bio Recent Development
7.25 Ultimovacs
7.25.1 Ultimovacs Corporation Information
7.25.2 Ultimovacs Description and Business Overview
7.25.3 Ultimovacs Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.25.4 Ultimovacs Products Offered
7.25.5 Ultimovacs Recent Development
7.26 Foresee Pharmaceuticals
7.26.1 Foresee Pharmaceuticals Corporation Information
7.26.2 Foresee Pharmaceuticals Description and Business Overview
7.26.3 Foresee Pharmaceuticals Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.26.4 Foresee Pharmaceuticals Products Offered
7.26.5 Foresee Pharmaceuticals Recent Development
7.27 Luye Pharma Group
7.27.1 Luye Pharma Group Corporation Information
7.27.2 Luye Pharma Group Description and Business Overview
7.27.3 Luye Pharma Group Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.27.4 Luye Pharma Group Products Offered
7.27.5 Luye Pharma Group Recent Development
7.28 Abbott
7.28.1 Abbott Corporation Information
7.28.2 Abbott Description and Business Overview
7.28.3 Abbott Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.28.4 Abbott Products Offered
7.28.5 Abbott Recent Development
7.29 Jiangsu HengRui Medicine
7.29.1 Jiangsu HengRui Medicine Corporation Information
7.29.2 Jiangsu HengRui Medicine Description and Business Overview
7.29.3 Jiangsu HengRui Medicine Prostate Cancer Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.29.4 Jiangsu HengRui Medicine Products Offered
7.29.5 Jiangsu HengRui Medicine Recent Development
8 Industry Chain and Sales Channels Analysis
For more information about this report, visit
Any questions or requirements, please do not hesitate to contact us.
About Us:
QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 15 years’ experience and professional research team in various cities over the world，QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 59,000 clients across five continents. Let’s work closely with you and build a bold and better future.
Contact Us
QY Research
E-mail: global@qyresearch.com
Tel: +1-626-842-1666(US) +852-5808-0956 (HK)
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
Website: https://us.qyresearch.com